Bronchial Genomic Classifier May Improve Lung Cancer Detection
the Cancer Therapy Advisor take:
A gene-expression classifier may improve the diagnostic performance of bronchoscopy in detecting pulmonary lesions that are suggestive of lung cancer, according to a recent study published in The New England Journal of Medicine.
Researchers led by Gerard Silvestri, MD, of the Medical University of South Carolina looked at 639 patients who were enrolled in 28 centers as part of the prospective AEGIS-1 and AEGIS-2 trials. Among them, 43 percent had undergone bronchoscopic examinations that were nondiagnostic for lung cancer, leading to invasive procedures after bronchoscopy in 35 percent with benign lesions.
They studied a gene-expression classifier in epithelial cells that was collected from normal-appearing mainstem bronchus in order to assess the probability of lung cnacer.
The researchers found that, in AEGIS-1, the classifier had a sensitivity of 88 percent and a specificity of 47 percent. In AEGIS-2, it had a sensitivity of 89 percent and a specificity of 47 percent.
Combination bronchoscopy and classifier had a sensitivity of 96 percent in AEGIS-1 and 98 percent in AEGIS-2. Among 101 patients who had intermediate pretest probability of cancer, negative predictive value of the classifier was 91 percent in those with nondiagnostic bronchoscopic examination.
“In intermediate-risk patients with a nondiagnostic bronchoscopic examination, a negative classifier score provides support for a more conservative diagnostic approach,” the authors concluded.
Gene-expression classifier may improve the diagnostic performance of bronchoscopy in detecting lung cancer.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Plastics and Cancer
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- Cabozantinib Shows Promising Activity in Osteosarcoma and Ewing Sarcoma
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- First-Line Alectinib Effective in Asian Patients With ALK-Positive Advanced NSCLC
- Pembrolizumab Alone or With Chemotherapy Prolongs OS in Recurrent/Metastatic HNSCC
- Pembrolizumab With Dabrafenib and Trametinib Shows Efficacy, But High TRAEs, in Melanoma
- Assays May Help Researchers Discover Factors Underlying Immunotherapy Response
- Atezolizumab Combo Improved PFS, OS in Stage IV Non-Small Cell Lung Cancer